European to North America Nordic Pharma has established a strong European footprint with recent expansion into Canada, suggesting opportunities to leverage cross-border partnerships or co-development deals to scale specialty products in North America.

Specialty and orphan focus The company concentrates on niche hospital and orphan products across rheumatology, women’s health, and critical care, indicating a potential in-licensing, distribution, or joint development deals for high unmet medical needs and hospital-based formularies.

Recent launches Lacrifill and other ophthalmic products are being launched in Europe, signaling active market entry and regulatory progress that can be leveraged for additional ophthalmology line extensions or regional distribution partnerships.

Acquisition and portfolio activity Historical emphasis on internal development and acquisitions, plus asset sales to a third party in 2026, implies a readiness to pursue strategic partnerships, asset acquisitions, or licensing deals to supplement growth and portfolio diversification.

Sustainability and credibility EcoVadis Silver Medal and top 15% recognition reflect governance and sustainability credibility that can be highlighted in partnering discussions to win tenders or enhance value propositions with customers prioritizing responsible suppliers.